George Jon C, Liner Ann, Hoit Brian D
Cardiovascular Research Center, Temple University School of Medicine, Philadelphia, Pennsylvania, USA.
Echocardiography. 2010 Jul;27(6):716-21. doi: 10.1111/j.1540-8175.2009.01107.x. Epub 2010 Mar 25.
Isoproterenol (ISO)-induced myocardial injury is widely used as an experimental animal model; however, the optimal route of delivery, i.e., subcutaneous (SC) versus intraperitoneal (IP) has not been clarified. We systematically compared changes in cardiac function (echocardiography, Doppler and strain imaging) and exercise capacity induced by ISO via SC versus IP delivery.
Twelve rats were used in this study and classified into three groups: Control (n = 2), SC-ISO (n = 5), and IP-ISO (n = 5), each receiving serial injections of ISO (100 mcg/kg) for 5 days (days 1-5). All rats underwent echocardiographic analysis of left ventricular function and functional capacity (FC) assessment on a treadmill protocol at baseline and post treatment. Hearts were excised and weighed at the end of the study.
Left ventricular (LV) systolic and diastolic dysfunctions were adequately induced by both SC and IP delivery: > or =13% reduction in fractional shortening, > or =12% increase in wall motion score index, and > or =35% increase in myocardial performance index; > or =49% increase in E/A ratio; > or =9% decline in anterior wall tissue velocity; > or =12% decline in circumferential and radial tissue strain and strain rates; > or =20% decline in FC; and > or =40% increase in echocardiographic LV mass and gross heart weight in both groups.
Short-duration ISO administration with serial injections via SC and IP routes induces significant myocardial dysfunction and impairs FC with few differences between both modalities.
异丙肾上腺素(ISO)诱导的心肌损伤被广泛用作实验动物模型;然而,最佳给药途径,即皮下(SC)与腹腔内(IP)给药,尚未明确。我们系统地比较了通过皮下与腹腔内给药的ISO诱导的心脏功能(超声心动图、多普勒和应变成像)变化以及运动能力。
本研究使用12只大鼠,分为三组:对照组(n = 2)、皮下注射ISO组(n = 5)和腹腔内注射ISO组(n = 5),每组连续注射ISO(100 mcg/kg)5天(第1 - 5天)。所有大鼠在基线和治疗后均接受左心室功能的超声心动图分析以及跑步机方案的功能能力(FC)评估。研究结束时切除心脏并称重。
皮下和腹腔内给药均充分诱导了左心室(LV)收缩和舒张功能障碍:缩短分数降低≥13%,壁运动评分指数增加≥12%,心肌性能指数增加≥35%;E/A比值增加≥49%;前壁组织速度下降≥9%;圆周和径向组织应变及应变率下降≥12%;FC下降≥20%;两组超声心动图左心室质量和心脏总重量增加≥40%。
通过皮下和腹腔内途径连续注射短期给予ISO可诱导明显的心肌功能障碍并损害FC,两种给药方式之间差异不大。